Clinical features and prognostic factors associated with malignant transformation of ovarian mature cystic teratoma

Purpose: To explore the clinical characteristics and identify potential prognostic factors associated with malignant transformation (MT) of ovarian mature cystic teratoma (MCT). Materials and Methods: This study analyzed 23 patients with MT of ovarian MCT at the present center during a ten-year period. The data were analyzed using Kaplan-Meier method. Results: The incidence of MT of ovarian MCT was 1.3%. The mean follow-up time was 44 months. The overall five-year survival rate was 69.6%. Patient age, tumor size, histology type, disease stage, and postoperative residual disease had a significant prognostic impact on overall survival. Elevated CA125 was associated with adverse outcomes. Conclusion: Age of patient, size of tumor, serum CA125, CA199, CEA, and SCCA levels, and presence of HPV are potential predictors of MT of ovarian MCT. Intraoperative frozen section analysis is essential in cases of suspected MT. Patient age, tumor size, histology, disease stage, and post-operative residual tumors are important factors affecting prognosis. CA125 level is associated with a poor prognosis.

Mature cystic teratoma; Malignant transformation; Prognostic factor

[1] Hackethal A., Brueggmann D., Bohlmann M.K., Franke F. E., Tinneberg H. R., Munstedt K.: “Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data”. Lancet. Oncol., 2008, 9, 1173.

[2] Mandal S., Badhe B.A.: “Malignant transformation in a mature teratoma with metastatic deposits in the omentum: a case report”. Case. Rep. Pathol. 2012., 2012, 568062.

[3] Crouet H., de Ranieri E., de Ranieri J.: “Secondary cancers arising in mature benign cystic teratomas of the ovary (dermoid cysts). Review of the literature apropos of a new case”.J. Gynecol. Obstet. Biol. Reprod. (Paris), 1986, 15, 1055.

[4] Dos Santos L., Mok E., Iasonos A., Park K., Soslow R.A., Aghajanian C., et al.: “Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature”. Gynecol. Oncol., 2007, 105, 321.

[5] Tangjitgamol S., Manusirivithaya S., Sheanakul C., Leelahakorn S., Thawaramara T. Jesadapatarakul S.: “Squamous cell carcinoma arising from dermoid cyst: Case reports and review of literature”. Int. J. Gynecol. Cancer., 2003, 13, 558.

[6] Desouki M.M., Fadare O., Chamberlain B. K., Shakir N., Kanbour-Shakir A.: “Malignancy associated with ovarian teratomas: frequency, histotypes, and diagnostic accuracy of intraoperative consultation”. Ann. Diagn. Pathol., 2015, 19, 103.

[7] Bal A., Mohan H., Singh S.B., Sehgal A.: “Malignant transformation in mature cystic teratoma of the ovary: report of five cases and review of the literature”.Arch. Gynecol. Obstet., 2007, 275, 179.

[8] Chiang A.J., Chen D.R., Cheng J.T., Chang T.H.: “Detection of human papillomavirus in squamous cell carcinoma arising from dermoid cysts ”.Taiwan. J. Obstet. Gynecol., 2015, 54, 559.

[9] Hirakawa T., Tsuneyoshi M., Enjoji M.: “Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis”. Am. J. Surg. Pathol., 1989, 13, 397.

[10] Kizaki Y., Nagai T.: “ Ovarian mature cystic teratoma with fistula formation into the rectum: a case report”. SpringerPlus., 2016, 5, 1700.

[11] Yarmohammadi H., Mansoori B., Wong V., Tacher V., Wilkins L.R., Pavlidakey P.G., Haaga J.R.: “Squamous cell carcinoma arising from ovarian mature cystic teratoma and causing small bowel obstruction”. J. Cancer. Res. Ther., 2014, 10, 770.

[12] Tosuner Z., Sonmez F.C., Arici D.S. Dansuk R.: “Carcinoid tumor arising in a mature cystic teratoma: A case report”. Oncol. Lett., 2015, 9, 2236.

[13] Park S.B., Kim J.K., Kim K.R., Cho K.S.: “Preoperative diagnosis of mature cystic teratoma with malignant transformation: analysis of imaging findings and clinical and laboratory data”.Arch. Gynecol. Obstet., 2007, 275, 25.

[14] Kawai M., Kano T., Kikkawa F., Morikawa Y., Oguchi H., Nakashima N., et al.: “Seven tumor markers in benign and malignant germ cell tumors of the ovary”.Gynecol. Oncol., 1992, 45, 248.

[15] Dede M., Gungor S., Yenen M.C., Alanbay I., Duru N.K. Hasimi A.: “CA19-9 may have clinical significance in mature cystic teratomas of the ovary”. Int. J. Gynecol. Cancer., 2006, 16, 189.

[16] Mori Y., Nishii H., Takabe K., Shinozaki H., Matsumoto N., Suzuki K., et al.: “Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary”. Gynecol. Oncol., 2003, 90, 338.

[17] Sakuma M., Otsuki T., Yoshinaga K., Utsunomiya H., Nagase S., Takano T., et al.: “Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases”. Int. J. Gynecol. Cancer., 2010, 20, 766.

[18] Yoshida K., Kajiyama H., Utsumi F., Mitsui H., Shibata K. Kikkawa F.: “Radiotherapy for persistent malignant transformation from mature cystic teratoma of the ovary”. J. Obstet. Gynaecol. Res., 2016, 42, 584.